Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.65 |
| ▸ | RAB9A | P51151 | 8/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 8/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30501370 | 1.00 | NPC1 (0.65) | NPC1RAB9AALDH1A1TSHRHPGD | |
| SCHEMBL20598829 | 0.81 | NPC1 (0.72) | NPC1RAB9AALDH1A1TSHRHPGD | |
| SCHEMBL20598652 | 0.81 | MAPKAPK2 (0.46) | NPC1RAB9AALDH1A1HPGDKMT2A | |
| SCHEMBL16106421 | 0.81 | MAPT (0.58) | NPC1RAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL20598140 | 0.79 | ALDH1A1 (0.67) | NPC1RAB9AALDH1A1TSHRHPGD | |
| SCHEMBL20598291 | 0.78 | IRAK4 (0.59) | NPC1RAB9AALDH1A1MAPK10KMT2A | |
| SCHEMBL30501503 | 0.78 | IRAK4 (0.59) | NPC1RAB9AALDH1A1MAPK10KMT2A | |
| SCHEMBL30501492 | 0.78 | IRAK4 (0.59) | NPC1RAB9AALDH1A1MAPK10KMT2A | |
| SCHEMBL20598761 | 0.78 | IRAK4 (0.59) | NPC1RAB9AALDH1A1MAPK10KMT2A | |
| SCHEMBL4775809 | 0.77 | MAPT (0.54) | NPC1RAB9AALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111032642-B | Kinase inhibitors and methods of making and using the same | 里格尔药品股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20210309655-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210309655-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-11059814-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11059814-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200181135-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-20200181135-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| EP-3645525-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | Rigel Pharmaceuticals, Inc. (US) | 2020-05-06 | — | — | EP | disclosed |
| CN-111032642-A | Kinase inhibitors and methods of making and using | 里格尔药品股份有限公司 | 2020-04-17 | — | — | CN | disclosed |
| US-10590121-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-10590121-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| WO-2019006126-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019006126-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| US-20190002455-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| US-20190002455-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002455-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | NPC1 2113/4885RAB9A 3145/4885ALDH1A1 2414/4885 |
| US-20210309655-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | NPC1 2113/4885RAB9A 3145/4885ALDH1A1 2414/4885 |
| US-10590121-B2 | Kinase inhibitors and methods for making and using | IRAK1, IRAK2, IRAK3 | NPC1 1531/4885RAB9A 3101/4885ALDH1A1 1343/4885 |
| US-20200181135-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | NPC1 2113/4885RAB9A 3145/4885ALDH1A1 2414/4885 |
| US-11059814-B2 | Kinase inhibitors and methods for making and using | IRAK1, IRAK2, IRAK3 | NPC1 1370/4885RAB9A 2995/4885ALDH1A1 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.